Cargando…

Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment

In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxygluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hongyan, Liu, Wanwan, Cheng, Ziting, Yao, Ke, Yang, Yu, Xu, Bohui, Su, Gaoxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666711/
https://www.ncbi.nlm.nih.gov/pubmed/28937584
http://dx.doi.org/10.3390/ijms18102029
_version_ 1783275354848231424
author Zhu, Hongyan
Liu, Wanwan
Cheng, Ziting
Yao, Ke
Yang, Yu
Xu, Bohui
Su, Gaoxing
author_facet Zhu, Hongyan
Liu, Wanwan
Cheng, Ziting
Yao, Ke
Yang, Yu
Xu, Bohui
Su, Gaoxing
author_sort Zhu, Hongyan
collection PubMed
description In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxyglucose (DG) is the targeting molecule, polyethylene glycol (PEG) helps to improve the dispersity and biocompatibility, 9-poly-d-arginine (9R) is employed to provide a positive surface charge and adsorb negative siRNA, and hydrazone bonds are pH-responsive and can avoid receptor-mediated endosomal recycling. Compared to GNS alone, 9R/DG-GNS (hydrazone) showed superior transfection efficiency. The expressions of cyclooxygenase-2 (COX-2) in HepG2 and SGC7901 cells were significantly suppressed by siRNA/9R/DG-GNS (hydrazone) complex. Notably, 9R/DG-GNS (hydrazone) possessed low cytotoxicity even at high concentrations in both normal cells and tumor cells. The combination treatment of siRNA/9R/DG-GNS (hydrazone) complex inhibited the cell growth rate by more than 75%. These results verified that the pH-responsive GNS complex is a promising siRNA delivery system for cancer therapy, and it is anticipated that near-infrared absorbing GNS with good photothermal conversion efficiency can be potentially used for photothermal therapy of tumors.
format Online
Article
Text
id pubmed-5666711
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56667112017-11-09 Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment Zhu, Hongyan Liu, Wanwan Cheng, Ziting Yao, Ke Yang, Yu Xu, Bohui Su, Gaoxing Int J Mol Sci Article In this work, we report the engineering of gold nanostars (GNS) to deliver small interfering RNA (siRNA) into HepG2 cells. The ligand DG-PEG-Lipoic acid (LA)-Lys-9R (hydrazone) was designed to functionalize GNS, and create the nanoparticles named as 9R/DG-GNS (hydrazone). In the ligand, 2-deoxyglucose (DG) is the targeting molecule, polyethylene glycol (PEG) helps to improve the dispersity and biocompatibility, 9-poly-d-arginine (9R) is employed to provide a positive surface charge and adsorb negative siRNA, and hydrazone bonds are pH-responsive and can avoid receptor-mediated endosomal recycling. Compared to GNS alone, 9R/DG-GNS (hydrazone) showed superior transfection efficiency. The expressions of cyclooxygenase-2 (COX-2) in HepG2 and SGC7901 cells were significantly suppressed by siRNA/9R/DG-GNS (hydrazone) complex. Notably, 9R/DG-GNS (hydrazone) possessed low cytotoxicity even at high concentrations in both normal cells and tumor cells. The combination treatment of siRNA/9R/DG-GNS (hydrazone) complex inhibited the cell growth rate by more than 75%. These results verified that the pH-responsive GNS complex is a promising siRNA delivery system for cancer therapy, and it is anticipated that near-infrared absorbing GNS with good photothermal conversion efficiency can be potentially used for photothermal therapy of tumors. MDPI 2017-09-22 /pmc/articles/PMC5666711/ /pubmed/28937584 http://dx.doi.org/10.3390/ijms18102029 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhu, Hongyan
Liu, Wanwan
Cheng, Ziting
Yao, Ke
Yang, Yu
Xu, Bohui
Su, Gaoxing
Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title_full Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title_fullStr Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title_full_unstemmed Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title_short Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment
title_sort targeted delivery of sirna with ph-responsive hybrid gold nanostars for cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666711/
https://www.ncbi.nlm.nih.gov/pubmed/28937584
http://dx.doi.org/10.3390/ijms18102029
work_keys_str_mv AT zhuhongyan targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT liuwanwan targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT chengziting targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT yaoke targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT yangyu targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT xubohui targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment
AT sugaoxing targeteddeliveryofsirnawithphresponsivehybridgoldnanostarsforcancertreatment